Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11666645 | 0.89 | SMN1; SMN2 (0.50) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL2104486 | 0.79 | TSHR (0.59) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL23308872 | 0.79 | TSHR (0.59) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL27673212 | 0.79 | TSHR (0.59) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL1631053 | 0.79 | TSHR (0.65) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL20502504 | 0.78 | TSHR (0.62) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL3374110 | 0.78 | KDM4E (0.62) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL6320584 | 0.76 | KDM4E (0.61) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL30746463 | 0.76 | TSHR (0.61) | TSHRATMSMN1; SMN2KDM4ELMNA | |
| SCHEMBL1667129 | 0.76 | KDM4E (0.75) | SMN1; SMN2KDM4ELMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574323-A | Dibenzothiophene sulfonyl covalent organic framework material and application thereof in thiadiazole and derivative photocatalytic synthesis | 三峡大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| CN-100432070-C | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | CN | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1693372-A1 | Novel Sulfamides and their use as endothelin receptor antagonists | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-23 | — | — | EP | disclosed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | BOLLI MARTIN | 2006-08-10 | — | — | US | disclosed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | disclosed |
| CN-1524079-A | Novel sulfonamides and their use as endothelin receptor antagonists | ������˹ҩƷ��˾ | 2004-08-25 | — | — | CN | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1345920-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
| EP-0170057-B1 | PROCESS FOR THE PREPARATION OF N-PHENYL(PYRIDYL) SULFONYL DIAMIDES | BASF Aktiengesellschaft (DE) | 1987-01-14 | — | — | EP | disclosed |
| EP-0170057-A2 | Process for the preparation of N-phenyl(pyridyl) sulfonyl diamides | BASF Aktiengesellschaft (DE) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | TSHR 3610/4885ATM 1331/4885SMN1; SMN2 3576/4885 |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | EDNRA, EDNRB, ECE2 | TSHR 1351/4885ATM 4221/4885SMN1; SMN2 1494/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | TSHR 481/4885ATM 4263/4885SMN1; SMN2 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.